December 26, 2017 / 3:33 AM / 6 months ago

BRIEF-Alembic Pharmaceuticals Says U.S. FDA Grants Orphan-Drug Designation To Rhizen Pharmaceuticals

Dec 26 (Reuters) - Alembic Pharmaceuticals Ltd:

* U.S. FDA GRANTS ORPHAN-DRUG DESIGNATION FOR TENALISIB TO RHIZEN PHARMACEUTICALS S.A. (RHIZEN) Source text - bit.ly/2C7DIYd Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below